Voyager Therapeutics adds proof its gene therapy for Parkinson’s can work, shares soar – Endpoints News
Endpoints News |
Voyager Therapeutics adds proof its gene therapy for Parkinson's can work, shares soar
Endpoints News The Cambridge, MA-based biotech has fleshed out its early-stage proof-of-concept data on VY-AADC01, offering new data that demonstrate a heightened efficacy for two higher doses of the gene therapy. Executives at Voyager tell me that they're heartened … Voyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced … Voyager Therapeutics (VYGR) Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced … Voyager's VY-AADC01 shows encouraging results in early-stage Parkinson's study; shares ahead 27% premarket |
